Gilead Sciences, Inc. vs Pfizer Inc.
Market value, revenue, profit, valuation and financial strength side by side, each from the company's own filings or market data, with its date.
In short
- Gilead Sciences, Inc. is the larger company by market value: $193.5 B against $170.7 B for Pfizer Inc., 1.1 times as much (market caps of Oct 26, 2026 for Gilead Sciences, Inc. and Oct 30, 2026 for Pfizer Inc.).
- Pfizer Inc. had more revenue: $62.6 B against $29.4 B for Gilead Sciences, Inc., both in the year to December 2025.
- Gilead Sciences, Inc. earned more: net income of $8.5 B against $7.8 B for Pfizer Inc.
- Gilead Sciences, Inc. keeps more of each dollar of sales: a net margin of 28.9% against 12.4% for Pfizer Inc.
- Pfizer Inc. employs more people: 75,000 against 17,000 at Gilead Sciences, Inc. Each employee brings in about $1,731,941 of revenue at Gilead Sciences, Inc. and $834,387 at Pfizer Inc.
Market value, the same start = 100
From Jan 2020: how each one's value moved, whatever its size.
Revenue by fiscal year
US$ billions, as reported in each year's annual results.
Side by side
| Measure | Gilead Sciences, Inc. GILD · #104 in the world | Pfizer Inc. PFE · #127 in the world |
|---|---|---|
| Profile | ||
| Country | 🇺🇸 USA | 🇺🇸 USA |
| Sector | Healthcare | Healthcare |
| Industry | Pharmaceutical | Pharmaceutical |
| Founded | 1987 | 1849 |
| Size | ||
| Market cap | $193.5 B | $170.7 B |
| Revenue | $29.4 B | $62.6 B |
| Net income | $8.5 B▲ best | $7.8 B |
| Employees | 17,000 | 75,000 |
| Valuation | ||
| P/E ratio | — | 42.3× |
| Price to sales | 6.3× | 2.7× |
| Price to book | 8.5× | 2.0× |
| Free cash flow yield | 4.9% | 5.3%▲ best |
| Profitability | ||
| Gross margin | — | 74.3% |
| Net margin | — | 12.4% |
| Return on equity | — | 8.9% |
| Growth | ||
| Revenue growth | — | -1.6% |
| Revenue growth, 3 years a year | — | -14.8% |
| Earnings per share growth | — | -3.5% |
| Financial strength | ||
| Debt to equity | — | 0.7× |
| Cash | ||
| Free cash flow margin | — | 14.5% |
| Strength scores | ||
| Piotroski F-score | — | 5 of 9 |
| Altman Z-score zone | — | — |
| Data as of | Market cap Oct 2026 | Market cap Oct 2026; ratios FY2025 |
▲ marks the better of the two where higher or lower is better; size and valuation multiples are marked for neither
Questions and answers#
Which is bigger, Gilead Sciences, Inc. or Pfizer Inc.?
Gilead Sciences, Inc. is the larger company by market value: $193.5 B against $170.7 B for Pfizer Inc., 1.1 times as much (market caps of Oct 26, 2026 for Gilead Sciences, Inc. and Oct 30, 2026 for Pfizer Inc.).
Which makes more money, Gilead Sciences, Inc. or Pfizer Inc.?
Pfizer Inc. had more revenue: $62.6 B against $29.4 B for Gilead Sciences, Inc., both in the year to December 2025. Gilead Sciences, Inc. earned more: net income of $8.5 B against $7.8 B for Pfizer Inc.
Which is more profitable, Gilead Sciences, Inc. or Pfizer Inc.?
Gilead Sciences, Inc. keeps more of each dollar of sales: a net margin of 28.9% against 12.4% for Pfizer Inc.
Which has more employees, Gilead Sciences, Inc. or Pfizer Inc.?
Pfizer Inc. employs more people: 75,000 against 17,000 at Gilead Sciences, Inc. Each employee brings in about $1,731,941 of revenue at Gilead Sciences, Inc. and $834,387 at Pfizer Inc.
More about Gilead Sciences, Inc.
- Gilead Sciences, Inc.: company page
- Who owns Gilead Sciences, Inc.?
- Gilead Sciences, Inc. market cap history
- Gilead Sciences, Inc. revenue by year
- How many employees does Gilead Sciences, Inc. have?
- Is Gilead Sciences, Inc. cheap or expensive?
- Gilead Sciences, Inc. against its peers: ranks and percentiles
More about Pfizer Inc.
Sources#
Every figure on this page comes from these, with the date shown next to it.